Pharmacists in Connellys Springs, NC Accepting Medicare
1 Pharmacists found. Showing 1 - 1
 Mr. Julie Granger, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 721 Malcolm Blvd, Connellys Springs, NC 28612 Phone: 828-874-5100 Fax: 828-874-2843 |
News Archive
FDA announces availability of $2 million for rare disease research
The U.S. Food and Drug Administration today announced the availability of $2 million in research grants to fund natural history studies in rare diseases. The aim is to collect data on how specific rare diseases progress in individuals over time so that knowledge can inform and support product development and approval. This will be the first time the FDA will provide funding through its Orphan Products Grants to conduct these types of studies for rare diseases.
Researchers show why mutations in a certain few genes, such as the p53 tumor suppressor gene, are found in different cancers
Scientists have identified some of the first genetic triggers for cancer as mutations in specific oncogenes or tumor suppressor genes. Full-blown tumors and metastatic cancers, however, often exhibit many genetic mutations, sometimes dozens in a given tumor. An important scientific question, and one with significant clinical implications, has been what happens after the initial mutation that leads to dangerous later-stage cancers with multiple damaged genes.
Could higher carnitine levels in the blood protect against severe COVID-19?
Researchers at the MRC Integrative Epidemiology Unit (IEU), Bristol Medical School, University of Bristol, Bristol, UK, found that carnitine and its derivative acetyl-carnitine provide a protective effect against severe COVID-19. Doubling of carnitine or acetyl-carnitine is tied to a 40-percent reduction risk of disease progression.
Tumor-targeting viral therapy slows neuroblastoma, malignant peripheral nerve sheath tumors
Researchers in a multi-institutional study led by Cincinnati Children's Hospital Medical Center slowed the growth of two particularly stubborn solid tumor cancers - neuroblastoma and peripheral nerve sheath tumors - without harming healthy tissues by inserting instructions to inhibit tissue growth into an engineered virus, according to study results published in the February 15 Cancer Research.
Celator announces expansion of research agreement with Cephalon
Celator Pharmaceuticals today announced that it has expanded its research agreement with Cephalon, Inc.. The research agreement provides for the utilization of Celator's proprietary technology in an ongoing drug development and life-cycle management program at Cephalon.
› Verified 6 days ago